![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » India’s Serum Institute Begins Manufacturing Codagenix’s COVID-19 Vaccine
India’s Serum Institute Begins Manufacturing Codagenix’s COVID-19 Vaccine
![India_shape.jpg](https://www.fdanews.com/ext/resources/test/Drug-Images4/India_shape.jpg?t=1600823036&width=430)
September 23, 2020
The Serum Institute of India has begun manufacturing New York-based Codagenix’s COVID-19 vaccine candidate CDX-005.
Delivered through the nose, CDX-005 uses a weakened form of the SARS-CoV-2 virus to generate a protective immune response.
The institute will manufacture the vaccine for large-scale safety and efficacy studies, and it will prepare to scale up production to meet global demand if the candidate proves successful.
Codagenix expects to begin phase 1 testing of the vaccine in the UK before the end of this year.
Upcoming Events
-
21Oct